Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure

American Journal of Hematology

Volumn 87, Issue 5, 2012, Pages 465-471

  Palladini, Giovanni ^a   Foli, Andrea ^a   Milani, Paolo ^a   Russo, Paola ^a   Albertini, Riccardo ^a   Lavatelli, Francesca ^a   Obici, Laura ^a   Perlini, Stefano ^b   Moratti, Remigio ^a   Merlini, Giampaolo ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART AMYLOIDOSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL PREDICTION;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID; AMYLOIDOSIS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GLOMERULAR FILTRATION RATE; HEART; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LIVER; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERIPHERAL NERVOUS SYSTEM; PERITONEAL DIALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; ROC CURVE;

EID: 84859923501     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23141     Document Type: Article

References (22)

1. Merlini G, Palladini G. Amyloidosis: Is a cure possible? Ann Oncol 2008; 19 (Suppl 4): iv63-66.
2. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445.
3. Dispenzieri A, Gertz M, Kyle R, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757.
4. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854-3858.
5. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010; 116: 3426-3430.
6. Merlini G, Seldin DC, Gertz MA. Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924-1933.
7. Gertz MA. How to manage primary amyloidosis. Leukemia 2011; 26: 191-198.
8. Mair J. Biochemistry of B-type natriuretic peptide-where are we now? Clin Chem Lab Med 2008; 46: 1507-1514.
9. Khalifeh N, Haider D, Hörl W. Natriuretic peptides in chronic kidney disease and during renal replacement therapy: An update. J Investig Med 2009; 57: 33-39.
10. Austin W, Bhalla V, Hernandez-Arce I, et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006; 126: 506-512.
11. Vickery S, Webb M, Price C, et al. Prognostic value of cardiac biomarkers for death in a nondialysis chronic kidney disease population. Nephrol Dial Transplant 2008; 23: 3546-3553.
12. Suresh M, Farrington K. Natriuretic peptides and the dialysis patient. Semin Dial 2005; 18: 409-419.
13. Roueff S, Martin E, Chauffert M, et al. Brain natriuretic peptide variations are linked to volume status in hemodialysis patients. Clin Nephrol 2008; 70: 508-513.
14. Obici L, Perfetti V, Palladini G, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11-22.
15. Gertz M, Leung N, Lacy M, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 2009; 24: 3132-3137.
16. Pinney JH, Lachmann HJ, Bansi L, et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol 2011; 29: 674-681.
17. Arbustini E, Verga L, Concardi M, et al. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002; 9: 108-114.
18. Gertz M, Comenzo R, Falk R, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
19. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
20. Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499-504.
21. Levey A, Bosch J, Lewis J, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
22. Wu A, Packer M, Smith A, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: A multisite study. Clin Chem 2004; 50: 867-873.